Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Oaknin

Showing results (41-50 of 173) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancerBradley J Monk, Luis Mas Lopez, Juan J Zarba, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 15, 2023
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
Journal of Ovarian Research|May 27, 2021
Management of advanced ovarian cancer in Spain: an expert Delphi consensusAndres Redondo, Ana Oaknin, Maria Jesus Rubio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2024
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical CancerAna Oaknin, Sharad A Ghamande, Yuka Kasamatsu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid TumoursAlexandra Leary, Ana Oaknin, José Manuel Trigo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 9, 2023
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601José Alejandro Perez-Fidalgo, Eva Guerra, Yolanda García, et al.
Gynecologic Oncology|February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerLucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 22, 2016
A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial CancerPatricia Pautier, Ignace Vergote, Florence Joly, et al.
JAMA Oncology|October 1, 2020
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical TrialAna Oaknin, Anna V Tinker, Lucy Gilbert, et al.
Pageof 18

Showing results (41-50 of 173) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancerBradley J Monk, Luis Mas Lopez, Juan J Zarba, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 15, 2023
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
Journal of Ovarian Research|May 27, 2021
Management of advanced ovarian cancer in Spain: an expert Delphi consensusAndres Redondo, Ana Oaknin, Maria Jesus Rubio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2024
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical CancerAna Oaknin, Sharad A Ghamande, Yuka Kasamatsu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid TumoursAlexandra Leary, Ana Oaknin, José Manuel Trigo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 9, 2023
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601José Alejandro Perez-Fidalgo, Eva Guerra, Yolanda García, et al.
Gynecologic Oncology|February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerLucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 22, 2016
A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial CancerPatricia Pautier, Ignace Vergote, Florence Joly, et al.
JAMA Oncology|October 1, 2020
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical TrialAna Oaknin, Anna V Tinker, Lucy Gilbert, et al.
Pageof 18